The Safety of (2R,3R)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butane-2,3-diol

(2R,3R)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butane-2,3-diol, also known as SRT651628, is a synthetic molecule that has been studied for its potential use in the treatment of various diseases, including cancer.
While the safety of this compound has not yet been fully established, studies have been conducted to assess its safety in the context of its potential therapeutic uses.

One of the primary concerns when studying the safety of a new compound is its potential toxicity to living cells.
In order to evaluate the toxicity of SRT651628, studies have been conducted in vitro, using cultured cancer cells, and in vivo, using animal models.
These studies have shown that SRT651628 has a low order of toxicity, meaning that it is not highly toxic to cells or animals at low doses.

Another important consideration in evaluating the safety of a new compound is its potential to cause side effects or adverse reactions.
While SRT651628 has shown promise as a potential therapeutic agent, it is important to thoroughly evaluate its safety and potential for adverse reactions before it can be used in humans.

The potential for SRT651628 to cause side effects or adverse reactions can be assessed by studying its pharmacokinetics and metabolism.
Pharmacokinetics refers to the study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
Metabolism refers to the chemical changes that occur in the body as a result of drug exposure.
Studies have shown that SRT651628 is rapidly absorbed by the body and undergoes extensive metabolism, which could result in the formation of potentially toxic metabolites.
However, the major metabolites of SRT65